Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Operating Expenses (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Operating Expenses for 16 consecutive years, with $45.8 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 12.63% to $45.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $227.1 million through Dec 2025, up 19.68% year-over-year, with the annual reading at $227.1 million for FY2025, 19.68% up from the prior year.
  • Operating Expenses hit $45.8 million in Q4 2025 for Ligand Pharmaceuticals, down from $60.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $81.5 million in Q1 2025 to a low of $24.9 million in Q2 2021.
  • Historically, Operating Expenses has averaged $43.5 million across 5 years, with a median of $40.2 million in 2021.
  • Biggest five-year swings in Operating Expenses: crashed 55.37% in 2023 and later soared 191.35% in 2025.
  • Year by year, Operating Expenses stood at $41.3 million in 2021, then skyrocketed by 70.74% to $70.5 million in 2022, then plummeted by 55.37% to $31.5 million in 2023, then soared by 66.72% to $52.4 million in 2024, then fell by 12.63% to $45.8 million in 2025.
  • Business Quant data shows Operating Expenses for LGNDZ at $45.8 million in Q4 2025, $60.5 million in Q3 2025, and $39.2 million in Q2 2025.